A Clinical Study on the Safety and Efficacy of SHJ002 Sterile Ophthalmic Solution in the Treatment of Corneal Erosion in Patients With Sjogren's Syndrome
Latest Information Update: 08 May 2025
At a glance
- Drugs SHJ 002 (Primary)
- Indications Sjogren's syndrome
- Focus Therapeutic Use
- Sponsors Sunhawk Vision Biotech
Most Recent Events
- 29 Apr 2025 Status changed from active, no longer recruiting to completed.
- 07 Jan 2025 Status changed from recruiting to active, no longer recruiting.
- 22 Jul 2024 Status changed from not yet recruiting to recruiting.